Pharm.D

Doctoral degree in Science, Engineering, Technology, Pharma from a recognized University or equivalent. Experience of working with national, international testing & certification laboratories, organizations.

MSc, PhD, PharmD, or MD. experience in medical communications. Medical writing experience. Demonstrate a command of assigned therapeutic areas and expertise with assigned products.

B.Pharm with experience in relevant field or M.Pharm experience in relevant field Or Pharm.D with experience in relevant field

A Prospective, Multicenter, Single-arm, Open-label, Phase IV, Post authorization Interventional Study to Assess the Safety and Efficacy of Asciminib in Indian Patients with Ph+ CML-CP without T315I Mutation, Previously Treated with two or more Tyrosine Kinase Inhibitors and Ph+ CML-CP with T315I Mutation

Evaluation of anti-inflammatory and immunomodulatory therapies using in vivo chronic inflammatory and autoimmune animal models such as psoriasis, colitis, and arthritis. Clinical and translational pharmacology focusing on patient-centric drug safety, pharmacovigilance, and outcome-based clinical investigations.

Project Development of Process for Montelukast KSM. Doctoral Degree in Chemical, Pharmaceutical Science, Pharma, MS from a recognized University or equivalent.

Master degree in Pharmacy, Clinical Pharmacology, Pharmacy Practice, and Clinical Research preferably with diploma in clinical research from the recognised institute.

Duties assigned to this title will require an in-depth knowledge of a specialized field, process, or discipline and may involve organizing and implementing complex research plans, the development of methods of research, testing and data collection, analysis and evaluation, and writing reports containing descriptive, analytical and evaluative content.

Applications are invited from suitably qualified and experienced candidates in the prescribed format to be copied on a plain paper for the temporary post mentioned below in the Clinical Research project A Phase II, Multi-center, Singlearm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K 5/y and SIK3 Inhibitor, in patients with Metastatic Triple Negative Breast Cancer.